Vall D'hebron Institut De Recerca — Clinical Trial Site

127 Registered trials

47 Currently recruiting

Organisation

Vall D'hebron Institut De Recerca

Location

Barcelona, Spain

Identifier

ORG-100008455

Address

Passeig De La Vall D'hebron 119-129, 08035, Spain

Departments

3000: Hematología
Alergologia
Alergology
Allergologia
Cap de secció. Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria
Department of Medicine
Dermatology
Gynaecologic cancer
Gynecologic Oncology
Hematology
Hepathology
Hospital Vall Hebron
Infectious diseases
Infectious Diseases and immunodeficiencies
Infectious Pathology and Immunodeficiencies Unit pediatric
Instituto de Investigación Germans Trias i Pujol (IGTP)
Internal medicine
Jefe de Sección Servicio de Oncología y Hem. Ped. Vall d’Hebron Barcelona Hosp. Campus
Medical Oncology
Medical Oncology Department
N/A
NA
Nephrology
Nephrology and Transplantation
Neumología
Neumology
Neurologia
Neurology
Neurophysiology Department - Sleep Unit
Nuclear Medicine
Oncología
Oncologia Medica
Oncology
Oncology - Phase I Unit
Oncology (VHIO)
Oncology-Genitourinary
Ophthalmology
Paediatric Onco-Haematology
Pediartic Oncology-Hematology
Pediatric hematology and oncology.
Pediatric in Oncology and Hematology
Pediatric Oncology and Hematology
Pediatrics
Retina
Rheumatology
Rhumatology
Servei de Cardiologia
Servicio de Hematologia
Servicio de Neumología
Servicio de Oncología
Servicio de Oncología Médica
Servicio de Oncología y Hematología
Servicio de Oncología y Hematología Pediátricas
Servicio Enfermedades Infecciosas.
Servicio Neumología
Unidad de Neuroimmunología Clínica
Unit of Inherited Metabolic Disorders and Rare Diseases
Urology

Clinical trials at this site (127)

Search interface

Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma Under evaluation

2024-514991-41-01 Upper Tract Urothelial Carcinoma. Upper urinary tract t 4
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Not authorised

2022-501697-19-00 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Not authorised

2023-508058-24-00 LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLOREC 1
Evaluation of the safety and efficacy of the drug AL8326 in the post-first treatment of small cell lung cancer. Not authorised

2023-509067-24-00 Small Cell Lung Cancer (SCLC) patients who need ≥2nd li 4
A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending

2023-509176-42-00 Obesity and T2D 11
Phase II Randomized Clinical Trial of quinacrine versus metronidazole in resistant giardiasis in children: Quin4Kids Pending

2023-510227-30-00 Intestinal giardiasis 9
Omalizumab's dose reduction or increase in the frequency of administration in patients who suffer from allergic severe asthma Pending

2025-520782-48-00 Asthma 6
A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting

2025-521521-33-00 Kidney transplant rejection 10 2026-04-02
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting

2025-521672-60-00 Metastatic or locally advanced SST2-positive neuroendoc 7 2025-12-19
Study of GS-5319 in Adults With Solid Tumors Recruiting

2025-522397-36-00 Advanced solid tumors 1 2025-12-18
STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting

2025-521276-59-00 Autosomal dominant polycystic kidney disease (ADPKD) 5 2025-12-16
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting

2025-520982-39-00 Philadelphia Chromosome Positive or ABL-class Philadelp 5 2025-12-09
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting

2024-512922-27-00 Mantle Cell Lymphoma (MCL) 4 2025-11-25
A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li… Recruiting

2024-518224-74-01 metastatic non-small-cell lung cancer 4 2025-02-07
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER). Recruiting

2023-504751-28-00 Exudative age-related macular degeneration 5 2024-09-24
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting

2023-504445-31-00 Carcinoma, Head and Neck 4 2024-09-19
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 LA/mGC/GEJC (locally advanced unresectable or metastati 9 2024-08-16
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer Recruiting

2023-504026-19-01 Prostate Cancer 5 2024-06-05
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors Recruiting

2022-500508-23-00 Advanced solid tumors 1 2022-10-28
Phase I/II clinical trial of autologous hematopoietic stem cell gene therapy in rag1-deficient severe combined immunodeficiency Recruiting

2023-510204-50-00 Severe combined immunodeficiency based on genetic defec 3 2021-07-23
ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting

2024-512657-24-00 Acute Lymphoblastic Leukaemia 10 2014-03-27
AMAZE 4: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea… Recruiting

2024-520443-16-00 Overweight or obesity, and obstructive sleep apnoea tre 5 2026-05-04